Tagrisso

News

WCLC: Chemo adds efficacy and side effects to AZ's Tagrisso

Giving AstraZeneca's EGFR tyrosine kinase inhibitor (TKI) inhibitor Tagrisso in combination with chemotherapy to patients with EGFR-mutated non-small cell lung cancer (NSC

News

ASCO: AZ gets a practice-changing win in lung cancer

The question of whether adjuvant treatment with AstraZeneca’s Tagrisso can help patients with EGFR-positive non-small cell lung cancer live longer has finally been answere

News

AZ posts first-line combo data for lung cancer drug Tagrisso

AstraZeneca’s top-selling drug Tagrisso is already widely used on its own as a first-line treatment for EGFR-mutated lung cancer, but new data suggests there can be benefi

News

AZ cancer drugs chalk up wins in early-stage lung cancer

Tagrisso and Imfinzi show benefit as neoadjuvant and adjuvant therapy for patients with NSLC.

News

Tagrisso paired with Hutchmed drug clears lung cancer test

EGFR inhibitors like AstraZeneca's Tagrisso have been hugely successful in treating EGFR-positive lung cancer, but the durability of treatment is often reduced by resistance mutations.

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

Scotland is world’s first country to greenlight Tagrisso for...

Scotland has given the green light to AstraZeneca’s Tagrisso for restricted use to treat adult patients with non-small cell lung cancer (NSCLC), making it the first country in the world to approve

WCLC: Chemo adds efficacy and side effects to AZ's Tagrisso

ASCO: AZ gets a practice-changing win in lung cancer

AZ posts first-line combo data for lung cancer drug Tagrisso

AZ cancer drugs chalk up wins in early-stage lung cancer

Tagrisso paired with Hutchmed drug clears lung cancer test

Scotland is world’s first country to greenlight Tagrisso for...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Tagrisso

Editor's Picks